Navigation Links
DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein

/p>

DIO-902 is an oral, once-daily drug being developed for the treatment of type 2 diabetes. It is a single enantiomer of racemic ketoconazole which suppresses cortisol production by inhibiting the 11 beta hydroxylase enzyme, the terminal step in the adrenal synthesis of cortisol. This novel mechanism of action makes DIO-902 a first-in-category cortisol inhibitor.

"Our unique approach to inhibition of cortisol synthesis offers the potential to address one of the underlying causes of type 2 diabetes, as well as multiple co-morbidities associated with both the disease, and its precursor, metabolic syndrome," said David A. Cory, Chief Executive Officer of DiObex, Inc. "DIO-902 offers patients the promise of effectively managing glycemia and lipids with a single medication. We are excited about the preliminary data generated to date and are rapidly progressing DIO-902 to the next stage of clinical development."

Data from various preclinical, epidemiological and clinical studies have suggested that a link exists between high cortisol levels and visceral adiposity, insulin resistance, and hyperglycemia -- common elements of the metabolic syndrome and type 2 diabetes.

The two-week trial with DIO-902 enrolled 37 patients with type 2 diabetes who were randomized to placebo, three different doses of DIO-902 ( 200 mg, 400 mg and 600 mg) or ketoconazole. Patients were either drug naove or on metformin, and had lipid-lowering agents washed out for at least 21 days prior to the first dose of the study drug. No serious adverse effects related to the study drug were reported. Liver function tests were carefully monitored, and no clinically meaningful changes were observed in any of the treated subjects. In fact, a number of subjects enrolled with mild transaminase elevations normalized during the two week treatment.

DiObex will conduct a multi-center, 16-week, phase 2b dose-ranging study with DIO-902; this study is scheduled to start enrolling patien
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, Inc. ... focused on delivering breakthrough 3D bioprinting technology, announced ... Chief Executive Officer, will present live at VirtualInvestorConferences.com ... you to join us for this Company update," ... on our commercial launch of the exVive3D Liver, ...
(Date:2/27/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today announced that ... on Tuesday, March 10, 2015. Rob Kill , ... Financial Officer, will present at 4:00 p.m. Pacific Time ... conference at the Ritz Carlton in Laguna ...
(Date:2/27/2015)... NEWTON, Mass. and JERUSALEM ... privately-held biopharma company developing octreotide capsules, its lead product ... of a $70 million Series E financing round. Participants ... and Sofinnova Ventures, and an undisclosed blue chip public ... F2 Capital, 7 Med Health Ventures, Abingworth and ARCH ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today announced ... covering the stimulator used in the Urgent® PC ... an office-based, non-surgical system, used to treat overactive ...
... LCAV ), a leading provider of laser vision correction ... management will present at the Lazard Capital Markets 8th Annual ... Eastern time. The conference is being held at the Pierre ... of the presentation will be available at the Investor Relations ...
Cached Medicine Technology:Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator 2
(Date:2/28/2015)... NV (PRWEB) February 28, 2015 My Shiney ... be sending a team to Las Vegas, Nevada for the ... Week is one of the leading consumer-goods tradeshows and My ... at this year’s event. My Shiney Hiney can be found ... fresh, modern design for the at-home personal hygiene brush and ...
(Date:2/27/2015)... February 27, 2015 Wireless Analytics, ... services, and one of the founders of ... for Bell Mobility within their CLEAN Platform™ (Communications ... Wireless Analytics’ newly developed Bell Mobility Data ... the Canadian wireless carrier’s business customers. , Wireless ...
(Date:2/27/2015)... February 27, 2015 Just a little ... for those suffering from Sjögren’s Syndrome after a new ... researchers at the University of Buffalo and Immco Diagnostics, ... research was to develop a new diagnostic test ... presence of new autoantibodies. Researchers aimed to develop a ...
(Date:2/27/2015)... Bethesda, MD (PRWEB) February 27, 2015 ... Foundation (Meso Foundation) and the National Cancer Institute ... Malignant Mesothelioma at the National Institutes of Health ... parts: one part is dedicated to medical professionals ... other is directed to the general public, including ...
(Date:2/27/2015)... February 27, 2015 Altec Products, Inc., ... their Sage ERP Document Management Partner of the Year. ... Sage CRM and other complimentary solutions for their customers ... side-by-side for many years to provide clients with paperless ... , “We are thrilled to recognize ADSS Global ...
Breaking Medicine News(10 mins):Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2
... drug and vaccine research is booming. According to a report ... George Institute for International Health, 16 new malaria vaccine candidates ... about to reach the market; and by 2011 we will ... , However, this unprecedented level of malaria R&D activity ...
... Oct. 4 Health information,technology (HIT) is a ... but it must be implemented to interact with ... according to a new report by,BearingPoint, prepared for ... is a nonpartisan independent body based in Washington,but ...
... Outlook Excluding Discrete Tax Items -, LIONVILLE, Penn., Oct. ... provided an update to its full year 2007,guidance. The Company ... its earnings per share guidance at between $2.27 and $2.37 ... in the third quarter a net discrete tax charge of ...
... Approval for Alternate ICG Manufacturing Site, TORONTO, ... a developer of real-time medical imaging systems and ... has received a,sufficient supply of ICG to immediately ... currently the exclusive suppliers of,indocyanine green (ICG) in ...
... to the,November 2006 Rand Corp. study, health care ... billion a year nationally and that 68,percent of ... adopted,tens of millions of newcomers, U.S.-born and foreign-born ... years to the U.S. population.,They will also consume ...
... 4 People who eat out,tend to consume more ... prefer takeout to the kitchen also tend to consume ... body needs to stay healthy. (Photo: http://www.newscom.com/cgi-bin/prnh/20071004/NYTHFNS2 ... said Peggy Fleming, Olympic figure,skating champion and HealthSaver spokesperson. ...
Cached Medicine News:Health News:Malaria product portfolio would benefit from greater cohesion amongst stakeholders 2Health News:Malaria product portfolio would benefit from greater cohesion amongst stakeholders 3Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 2Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 3Health News:New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care 4Health News:West Pharmaceutical Services Updates Annual Guidance 2Health News:West Pharmaceutical Services Updates Annual Guidance 3Health News:Novadaq Resumes Normal Business Operations by Securing ICG for SPY 2Health News:Novadaq Resumes Normal Business Operations by Securing ICG for SPY 3Health News:Message for Activists at Latino National Congreso Convention: Amnesty Will Exacerbate National Problems and Turn the U.S. into Another Mexico 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Cook Your Way to a Healthy Diet 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Cook Your Way to a Healthy Diet 3Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Cook Your Way to a Healthy Diet 4
Performa cemented stem....
M2 cemented hip stem....
Porous foundation 480 series....
Cemented foundation 460 series....
Medicine Products: